Bicara Therapeutics Inc.
BCAX
$9.43
-$0.005-0.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.46M | 6.75M | 4.76M | 3.63M | 3.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.79M | 26.64M | 20.63M | 17.56M | 15.37M |
| Operating Income | -41.79M | -26.64M | -20.63M | -17.56M | -15.37M |
| Income Before Tax | -36.77M | -20.77M | -17.48M | -14.78M | -12.51M |
| Income Tax Expenses | 72.00K | 186.00K | -- | 500.00 | 1.00K |
| Earnings from Continuing Operations | -36.85M | -20.96M | -17.48M | -14.78M | -12.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.85M | -20.96M | -17.48M | -14.78M | -12.51M |
| EBIT | -41.79M | -26.64M | -20.63M | -17.56M | -15.37M |
| EBITDA | -41.77M | -26.62M | -20.61M | -17.55M | -15.36M |
| EPS Basic | -0.68 | -0.39 | -1.60 | -19.09 | -18.94 |
| Normalized Basic EPS | -0.42 | -0.24 | -1.00 | -11.93 | -11.84 |
| EPS Diluted | -0.68 | -0.39 | -1.60 | -19.09 | -18.94 |
| Normalized Diluted EPS | -0.42 | -0.24 | -1.00 | -11.93 | -11.84 |
| Average Basic Shares Outstanding | 54.46M | 54.42M | 10.90M | 774.00K | 660.30K |
| Average Diluted Shares Outstanding | 54.46M | 54.42M | 10.90M | 774.00K | 660.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |